Adrenal Gland Pheochromocytoma
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Adrenal Gland Pheochromocytoma is an early-stage landscape with 7 programs across 6 companies. The most active players are Novartis, Pfizer, Viatris Specialty LLC. 4 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Novartis
1 program
Pfizer
1 program
Viatris Specialty LLC
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
1 program
Albireo, an Ipsen Company
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
71%
Small molecule
5 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)